





FIGURE 2
















**TEF-3** (6000 bps)






**CAP-1** (7076 bps)






**CAP-1** (7076 bps)




DNAse 1 hypersensitivity mapping of VEGFA


Summary of results:

	hyper sites			cells	[VEGF] (pg/ml)
	- <del>+</del> ++ ++ ++	_ <del>\</del> _ <del>\</del> ++ ++ _ <del>\</del> _+	human	U87MG Hela Hep3B 293 1º SkMc	11000 422 268 2 443 908
<b>+ + + +</b>	** * *	<u>*</u>	rat	RAT2 H9c2(2-1) 1º aorta SMC	891
-3000 -2000 HRE	-500	+1		-	+1000
					_





Conserved regulatory elements in the '-1000' accessible region:



٠ ;




Figure 12




Figure 13






Figure 14



F19.15

Ŧ **\$** 



F19.16






FIG. 17



F161, 18



÷ ;

FIG 19





FIG. 20



F1G. 21





FIG. 22







FIG. 24

- 5'-HO-TAGAAGGCACAGICGAGGACTTATCCTAGCCTCTGAATACTTTCAACAAGTTACACCCTT-P-3'-E(SEQ ID NO: 7)
  - (SEQ ID NO: 8) 3'-HO-AAAAAAATCTTCCGTGTCAGCTCCTGAATAGGATCGGAGACTTATGAAAGTTGTTCAATGTGGGA-OH-5'

Figure 26



## Figure 27

